Melbourne Health
Welcome,         Profile    Billing    Logout  
 17 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wong, Eric
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Active, not recruiting
3
270
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
ImmuneSense, NCT04485949: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Active, not recruiting
2
93
US
IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide
Imvax
Glioblastoma
01/25
07/27
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
08/24
03/25
NCT04129515: NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Not yet recruiting
1/2
30
US
NovoTTF-200A, Pembrolizumab, Keytruda®
Brown University, NovoCure Ltd.
Metastatic Melanoma, Melanoma Brain Metastasis
01/25
01/27
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
VICTORY, NCT05005299: Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Recruiting
1
18
RoW
Venetoclax, Venclaxta, Fludarabine, Cyclophosphamide
Melbourne Health
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma
03/26
03/26
Evans, Andrew
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Active, not recruiting
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
09/24
10/24
NCT05404945: Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Recruiting
2
44
US
Pembrolizumab, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine, Brentuximab vedotin
University of Virginia, Merck Sharp & Dohme LLC
Classical Hodgkin Lymphoma
10/27
10/27
ADROIT, NCT04071847: Abbott DBS Post-Market Study of Outcomes for Indications Over Time

Recruiting
N/A
1000
Europe, US, RoW
Deep Brain Stimulation (DBS)
Abbott Medical Devices
Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
09/29
09/30
Walt, Anneke van der
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
Ritchie, David
C-SMART, NCT04534725: COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Completed
3
441
RoW
Interferon alfa, Selinexor, Lenzilumab
Peter MacCallum Cancer Centre, Australia
Cancer, Covid19, Respiratory Viral Infection
11/22
04/23
ACTRN12619000581167: Brentuximab Vedotin in combination with donor lymphocyte infusions for Hodgkin lymphoma relapsing or persisting after allogeneic stem cell transplantation

Recruiting
2
10
 
Melbourne Health, Millenium Pharmaceuticals
Hodgkin lymphoma
 
 
NIVALLO, NCT03146468: Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

Active, not recruiting
2
14
RoW
Nivolumab Injection, Opdivo
Melbourne Health
Haematological Malignancy
03/22
03/22
ACTRN12620001339943p: REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT) Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia

Not yet recruiting
1/2
20
 
The Royal Melbourne Hospital, Maddie Riewoldt's Vision
One of the health conditions being studied in this trial will be Poor Graft Function ; One of the health conditions being studied in this trial will be Aplastic Anaemia
 
 
ACTRN12620001339943: REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT) Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia

Recruiting
1/2
20
 
The Royal Melbourne Hospital, Maddie Riewoldt's Vision
One of the health conditions being studied in this trial will be Poor Graft Function , One of the health conditions being studied in this trial will be Aplastic Anaemia
 
 
ACTRN12617000473369: A clinical trial to evaluate the safety of nivolumab for relapsed or residual haematological cancers after blood or bone marrow transplantation

Active, not recruiting
1/2
14
 
Melbourne Health, Bristol-Myers Squibb
Haematological malignancies
 
 
ACTRN12619000556145: Maintenance treatment with low-dose lenalidomide after allogeneic stem cell transplantation for patients with acute myeloid leukaemia or myelodysplastic syndrome

Recruiting
1
20
 
Melbourne Health, Celgene
Acute myeloid leukaemia , Myelodysplastic syndrome
 
 
ACTRN12622000308796: Short-course treatment with venetoclax prior to non-myeloablative conditioning allogeneic stem cell transplantation for patients with haematological malignancies.

Recruiting
1
18
 
Melbourne Health, The Commonwealth of Australia - Medical Research Future Fund (MRFF)
Acute leukaemia (myeloid and/or lymphoid, or biphenotypic), Myelodysplastic syndrome, Chronic lymphocytic leukaemia, B-cell non-Hodgkin lymphoma, Plasma cell myeloma
 
 
VICTORY, NCT05005299: Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Recruiting
1
18
RoW
Venetoclax, Venclaxta, Fludarabine, Cyclophosphamide
Melbourne Health
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma
03/26
03/26
Kalman, Jonathan M
OCEAN, NCT02168829: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Active, not recruiting
4
1284
Europe, Canada, RoW
Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc
Atrial Fibrillation, Stroke
07/25
08/25
NCT06223789: VOLT-AF IDE Clinical Study

Recruiting
N/A
435
Europe, Canada, US, RoW
Pulsed Field Ablation
Abbott Medical Devices
Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
01/26
01/26
STARAF3, NCT04428944: STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

Recruiting
N/A
615
Europe, Canada, Japan, US, RoW
Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI), Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers), Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)
McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal Heart Institute
Atrial Fibrillation
08/26
01/27
Koo, Ray Mun
VICTORY, NCT05005299: Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Recruiting
1
18
RoW
Venetoclax, Venclaxta, Fludarabine, Cyclophosphamide
Melbourne Health
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma
03/26
03/26
Koldej, Rachel
VICTORY, NCT05005299: Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Recruiting
1
18
RoW
Venetoclax, Venclaxta, Fludarabine, Cyclophosphamide
Melbourne Health
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma
03/26
03/26
Ugalde, Melissa
No trials found

Download Options